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Minireviewp53: Death Star
able to induce the defensive p53 response to oncogeneKaren H. Vousden*
Regulation of Cell Growth Laboratory activation, and in mice deletion of ARF strongly acceler-
ates tumor development (Sherr and Weber, 2000).NCI at Frederick
Frederick, Maryland 21702 The ability of ARF to connect oncogene activation
with the p53 pathway has prompted the search for
mechanisms that regulate ARF, which, like p53, is ex-
pressed at very low levels in normal cells. ARF expres-
From among the cast of thousands that appear to play
sion can be directly activated by the transcription factors
a role in the regulation of programmed cell death, p53
DMP1 and E2F1, or downregulated by factors such as
has emerged as one of the leading stars. p53 is a protein
Twist and Bmi1. The induction of ARF following activa-
of many talents, including activation of cell cycle arrest,
tion of oncogenes such as Myc, Ras, and E1A may
senescence, and differentiation. The special appeal of
therefore, in part, reflect the activation of E2F1, and both
p53, however, is as an apoptotic superhero, a protein
Twist and Bmi1 can counteract this oncogene-induced
that functions to selectively destroy stressed or abnor-
increase in ARF expression. Now a recent study has
mal cells, thereby protecting the organism from cancer
identified DAP kinase, another protein with the charac-
development. The key contribution of p53’s apoptotic
teristics of a tumor suppressor, as an additional player
activity to tumor suppression raises two quintessential
in this pathway (Raveh et al., 2001). DAP kinase plays
questions: what spurs p53 into action and how does
a role in the induction of ARF and stabilization of p53
p53 implement the death sentence? Several recent pub-
in response to Myc and E2F1 overexpression (Figure 1)
lications have thrown some interesting light on both
and both Myc and E2F1 were shown to upregulate DAP
issues.
kinase activity. The identification of a kinase in the ARFRules of Engagement: Regulation and Activation
pathway is extremely provocative, although so far theof p53
critical targets for DAP kinase phosphorylation remain
Since p53 is such a proficient inhibitor of cell growth,
unknown.
restraint of p53 activity during normal growth and devel-
The ability of mitogenic signals, such as deregulated
opment is of paramount importance. p53 function is
Myc, Ras, or E2F-1, to lead to the activation of p53
controlled through several mechanisms, one of the most
provides an effective mechanism to prevent abnormal
effective being regulation of protein stability. Central to
proliferation associated with tumor development. How-
this process is MDM2, an E3 ligase that targets both
ever, these fail-safe pathways pose a potentially serious
p53 and itself for ubiquitination. This function of MDM2
problem to cells that want to undergo legitimate prolifer-
has been shown to play a role in allowing export of p53
ation. Clearly the activation of p53 needs to be damp-
from the nucleus to the cytoplasm, and degradation of
ened in some way to allow normal growth, and recently
p53 by the proteasome (Vousden and Vande Woude,
a couple of strategies to temper the induction of p53
2000). MDM2 is a transcriptional target of p53, creating
by Ras have been described. In one system, the ability
a negative feedback loop where p53 activates expres-
of Ras to directly activate expression of MDM2 provides
sion of MDM2, which keeps p53 levels low during normal
a foil for the activation of ARF, which is also induced
growth and development. Activation of p53 in response
by Ras and inhibits MDM2 function (Ries et al., 2000)
to cellular stress such as DNA damage, oncogene acti-
(Figure 1). Similarly JunD, which is activated by Ras,
vation, telomere erosion and hypoxia is mediated, at
can negatively regulate ARF expression, again counter-
least in part, by inhibition of MDM2 and rapid stabiliza-
balancing the ability of Ras to activate ARF (Weitzman
tion of the p53 protein. Depending on the activating
et al., 2000). It would appear that the success of normal
signal, several mechanisms to perturb MDM2 function
have now been described, including phosphorylation of
p53 and MDM2 to block the interaction between the two
proteins, or selective downregulation of MDM2 expres-
sion. Of particular interest has been the discovery that
several oncogenes can induce stabilization of p53 by
enlisting the activity of ARF, a protein that functions by
binding directly to MDM2, inhibiting the ubiquitination
of p53 and allowing accumulation of p53 in the nucleus.
Although activation of ARF and stabilization of p53 alone
is not sufficient to induce death in all cell types, upregu-
lation of p53 in this way strongly sensitizes cells to die
in response to other insults such as DNA damage, loss
of survival signals, or additional apoptotic signals in-
duced by the oncogenes themselves. Loss of ARF Figure 1. Activation of E2F1 and Myc Lead to Induction of ARF, in
Part through DAP Kinase, thus Inhibiting MDM2 and Stabilizing p53makes cells much easier to transform, since they are less
Mitogenic signaling by Ras can activate p53 through ARF, but in
normal cells this protective response is dampened by concomitant
activation of MDM2 and inhibition of ARF by JunD.* E-mail: vousden@ncifcrf.gov
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cell division depends on the intricate coordination of
signals to allow proliferation without simultaneous acti-
vation of cell cycle arrest or cell death. Disruption of
this precarious balancing act, through unusually high
mitogenic signals or loss of normal survival signals, acti-
vates the strong safeguards that inhibit cell growth and
so protect against these types of abnormalities.
Natural Born Killer: Apoptotic Functions of p53
Having activated p53, the second burning question be-
comes, how does p53 function, particularly in the induc-
tion of apoptosis? The best understood activity of p53
is its ability to function as a transcription factor that can
induce or repress expression of a large and growing
number of genes, although less well defined transcrip-
tionally independent activities of p53 have also been Figure 2. The Two Major Apoptotic Pathways in Cells Can Be Acti-
described (Bates and Vousden, 1999). The importance vated by p53
of transcriptional regulation by p53 has been demon- Alterations in mitochrondrial membrane potential and/or cyto-
strated in many studies, most recently by the generation chrome c release may result from transcriptional activation of BH3
containing proteins such as Noxa or Bax, or even localization ofof mice or embryonic stem cells in which substitution
p53 itself to the mitochondria (Marchenko et al., 2000). Signalingof a transcriptionally inactive mutant p53 for the wild-
from death receptors is elevated following transcriptional activationtype protein resulted in loss of cell cycle arrest and
of receptors such as DR5 and Fas (Bates and Vousden, 1999), or
apoptotic functions (Chao et al., 2000; Jimenez et al., death domain containing proteins like PIDD. Transcriptionally inde-
2000). Although the ability of p53 to repress transcription pendent activities of p53 such as relocalization of death receptors
correlates well with some activities, particularly the in- from the Golgi to the cell surface (Bennett et al., 1998) would also
engage this pathway.duction of apoptosis, the mechanisms and requirements
for p53-mediated transcriptional repression remain elu-
sive, and it is the activation of gene expression by p53 domain containing protein, that would be predicted to
that has received the lion’s share of attention. Transcrip- interact with the complex that transmits the apoptotic
tional activation of the p21WAF1/CIP1 cyclin-dependent ki- signal from the death receptor (Lin et al., 2000). Although
nase inhibitor plays a key role in the induction of cell by no means the only apoptotic genes that can be tar-
cycle arrest by p53, but there does not appear to be a geted by p53, these new members of the p53-inducible
similar single critical apoptotic target. Bax, one of the club have passed the acid test for bona fide mediators
first apoptotic genes shown to be regulated by p53, is of p53 apoptosis, in that each of them has been shown
not induced by p53 under all circumstances, and is not to be required for the full apoptotic response, under
absolutely required for p53-mediated death. Numerous some conditions at least. Most of this evidence has been
other possible apoptotic targets have been described
gleaned from antisense experiments in tissue culture
over the past years, including several redox-related
cells, and we await with interest the consequence of
genes which led Polyak and colleagues to propose a
deleting these genes in mice.
model in which p53 regulates apoptosis through genera-
Judgement Day: Choice of Response to p53tion of reactive oxygen species (reviewed in Bates and
Maybe one of the most intriguing questions about p53’sVousden, 1999). It is now becoming apparent that there
apoptotic response is why do some cells show it, andwill be an abundance of genes that can mediate p53-
others not? Or maybe even more importantly, why dodependent cell death, although as yet it is unclear
transformed versions of some cell types die in responsewhether each contributes a part to the full response, or
to p53, while their normal counterparts show a poten-whether specific subsets of these genes are required for
tially reversible cell cycle arrest? This differential be-death in different cell types, or in response to different
tween normal and tumor cells has great potential in thesignals.
development of new cancer therapies based on reacti-p53 can directly engage each of the major apoptotic
vation of p53, which might preferentially kill tumor cells,pathways in the cell, stimulating both death receptor
while sparing normal tissue. Clearly not all cell typessignaling and mitochrondrial perturbations, including
require transformation to be sensitive to p53-inducedcytochrome c release (Figure 2). Loss of caspase 9 or
death, and inhibition of the p53-mediated apoptotic re-Apaf-1 renders mouse fibroblasts resistant to p53-depen-
sponse in normal gut epithelium and hematopoietic cellsdent apoptosis (Soengas et al., 1999), and similarly, cas-
has been proposed as a mechanism to prevent somepase 8 has been shown to play a role in transcriptionally
of the side effects of chemotherapeutic drugs (Komarovindependent apoptotic activities of p53 (Ding et al.,
et al., 1999). Nevertheless, the notion that for some tis-2000). Several recently described p53 transcriptional
sues, at least, p53 mediates tumor-specific killing hastargets encode proteins that localize to the mitochondria
prompted much optimism for the success of p53-basedand affect mitochondrial membrane potential, an activity
therapies.that sends a strong apoptotic signal through this path-
One interesting question to emerge from these studiesway. These include Noxa (Oda et al., 2000a), a protein
concerns the contribution, if any, of p53 to the choicecontaining a BH3 domain that interacts with the antiapo-
of response (Figure 3). Although various p53 mutantsptotic Bcl2 protein, and p53AIP1 (Oda et al., 2000b), a
have demonstrated a separation of apoptotic and cellnovel protein with no known homologs. A recent addi-
tion to the death receptor pathway is PIDD, a death cycle arrest functions, it is possible that p53 plays no
Minireview
693
and different forms of p53 can activate cell cycle arrest
or apoptotic target genes. It has been noted that the
abundance of p53 can affect the choice of response,
with low amounts of p53 leading to cell cycle arrest
which turns to apoptosis as p53 levels increase. One
simple explanation for this observation is that the pro-
moters driving the apoptotic target genes bind p53 with
a lower affinity, and are thus only activated when p53
induction is high or prolonged. In an extension of this
model, promoter binding can also be regulated by modi-
fications of p53, and a recent report has shown that
phosphorylation of p53 on serine 46 governs its ability
to regulate expression of at least one apoptotic target,
p53AIP1 (Oda et al., 2000b). Interestingly, phosphoryla-
tion of serine 46 was shown to correlate with the onsetFigure 3. Activation of p53 Can Lead to the Expression of Cell Cycle
Arrest and Apoptotic Target Genes of apoptosis, suggesting that this modification allows
In the first model (p53 dumb), the contribution of p53 to the induction p53 to function in the induction of cell death. Although
of these two groups of genes is the same under all conditions, the mechanism by which phosphorylation regulates
although additional, independent transcription factors may play a p53’s transcriptional activity is not known, there are
role in differentially regulating expression. In the second model (p53
several intriguing possibilities. Phosphorylation couldsmart), p53 itself is responsible for the differential expression of the
result in slight changes in the conformation of p53, whichapoptotic genes. This could be a consequence of higher overall
alter DNA binding specificity. Alternatively, modificationlevels of p53 in the cell, or modifications of p53 that affect DNA
binding or the interaction with transcriptional coactivators. of p53 may affect its ability to interact with coactivators
that are necessary specifically for expression of apo-
ptotic genes. JMY, for example, is a cofactor that selec-
tively contributes to the activation of only a subset of p53role in determining how the cell will respond, but always
responsive genes, thereby augmenting the apoptoticsends exactly the same signals after activation, includ-
response to p53 (Shikama et al., 1999).ing induction of both cell cycle arrest and apoptotic
Several modifications of p53 have been shown to reg-target genes. This notion is supported by the observa-
ulate DNA binding and transcriptional activity, includingtion that inhibition of p53-induced apoptosis reveals a
phosphorylation, acetylation, sumoylation, and glyco-concomitant p53-dependent cell cycle arrest. In this
sylation, providing plenty of mechanisms by which direct“p53 dumb” model, activation of p53 always results in
modification of p53 itself could regulate the choice ofan apoptotic signal, which is either impeded by survival
response. It is unclear whether modifications of p53 thatsignals, or augmented to reach the threshold level re-
allow expression of apoptotic targets diminish the abilityquired to kill the cells by additional, independent apo-
to activate cell cycle arrest genes, although the apparentptotic signals. Certainly, oncogenes such as Myc or
retention of the cell cycle arrest response in dying cellsE2F1 can activate p53-independent apoptotic signals,
suggests that versions of p53 that can drive cell deathin addition to activating p53 itself, and convergence of
retain the ability to activate the other responses. It isboth oncogene- and p53-induced signals is necessary
easy to conceive of models in which survival signalsto efficiently kill many cell types. Although generally
lead to modification of p53 so that only cell cycle arrestconsistent with much of the available evidence, some
genes can be activated, or in which oncogenes sendadaptation of the p53 dumb model is required to accom-
signals that modify p53 to allow expression of apoptoticmodate the observation that cell cycle arrest and apo-
targets. How much of this speculation is based in factptotic target genes of p53 can be differentially regulated,
remains to be seen, but given the intense interest in alland that expression of some p53-inducible apoptotic
aspects of the p53 story it is unlikely that these questionsgenes is activated only in cells undergoing p53-depen-
will remain unanswered for long.dent death (Attardi et al., 2000; Relaix et al., 2000). In a
variation of this model, p53 functions in the same way
under all circumstances, but the success of transcrip- Selected Reading
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